描述 |
Bedvitmab(ZTS-00508841)是一种针对神经生长因子(NGF)的犬单克隆抗体(mAb)。Bedvitmab抑制NGF与原肌球蛋白受体激酶A(trkA)和p75神经营养素受体(p75NTR)受体的相互作用。Bedvitmab可用于研究狗的骨关节炎疼痛[1][2]。
|
相关类别 |
|
体内研究 |
Bedvitmab(0.5-1 mg/kg;皮下注射28天)减轻与犬骨关节炎相关的疼痛[1]。 Bedvitmab(1 mg/kg;每月皮下注射;3倍和10倍剂量倍数)与 卡普罗芬(HY-B1227)共同给药,在正常实验室比格犬中耐受性良好[2]。
|
参考文献 |
[1]. Corral MJ, et, al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021 Nov;48(6):943-955. [2]. Krautmann M, et, al. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. Vet J. 2021 Oct;276:105733.
|